Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies

Adam Khorasanchi; Karan Jatwani; Lingbin Meng; Katharine A. Collier; Debasish Sundi; Shawn Dason; Eric A. Singer; Dharmesh Gopalakrishnan; Amir Mortazavi; Gurkamal Chatta; Yuanquan Yang

doi:10.3390/cancers16244127

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies

Adam Khorasanchi, Karan Jatwani, Lingbin Meng, Katharine A. Collier, Debasish Sundi, Shawn Dason, Eric A. Singer, Dharmesh Gopalakrishnan, Amir Mortazavi, Gurkamal Chatta, Yuanquan Yang

Research output: Contribution to journal › Review article › peer-review

Abstract

Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite definitive treatment, many patients with high-risk localized disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes the current evidence for neoadjuvant immunotherapy in patients with localized high-risk GU cancers including renal cell carcinoma, urothelial carcinoma, prostate cancer, penile squamous cell carcinoma, and testicular germ cell tumors. We also discuss ongoing clinical trials and candidate biomarkers to optimize patient selection and improve treatment outcomes.

Original language	English
Article number	4127
Journal	Cancers
Volume	16
Issue number	24
DOIs	https://doi.org/10.3390/cancers16244127
State	Published - Dec 2024
Externally published	Yes

Keywords

immune checkpoint inhibitors
immunotherapy
neoadjuvant
penile squamous cell carcinoma
prostate cancer
renal cell carcinoma
testicular germ cell tumors
urothelial carcinoma

Access to Document

10.3390/cancers16244127

Cite this

@article{ccec94aff2274cfe9b79dcf11f5c36d2,

title = "Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies",

abstract = "Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite definitive treatment, many patients with high-risk localized disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes the current evidence for neoadjuvant immunotherapy in patients with localized high-risk GU cancers including renal cell carcinoma, urothelial carcinoma, prostate cancer, penile squamous cell carcinoma, and testicular germ cell tumors. We also discuss ongoing clinical trials and candidate biomarkers to optimize patient selection and improve treatment outcomes.",

keywords = "immune checkpoint inhibitors, immunotherapy, neoadjuvant, penile squamous cell carcinoma, prostate cancer, renal cell carcinoma, testicular germ cell tumors, urothelial carcinoma",

author = "Adam Khorasanchi and Karan Jatwani and Lingbin Meng and Collier, {Katharine A.} and Debasish Sundi and Shawn Dason and Singer, {Eric A.} and Dharmesh Gopalakrishnan and Amir Mortazavi and Gurkamal Chatta and Yuanquan Yang",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = dec,

doi = "10.3390/cancers16244127",

language = "English",

volume = "16",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "24",

}

TY - JOUR

T1 - Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies

AU - Khorasanchi, Adam

AU - Jatwani, Karan

AU - Meng, Lingbin

AU - Collier, Katharine A.

AU - Sundi, Debasish

AU - Dason, Shawn

AU - Singer, Eric A.

AU - Gopalakrishnan, Dharmesh

AU - Mortazavi, Amir

AU - Chatta, Gurkamal

AU - Yang, Yuanquan

PY - 2024/12

Y1 - 2024/12

N2 - Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite definitive treatment, many patients with high-risk localized disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes the current evidence for neoadjuvant immunotherapy in patients with localized high-risk GU cancers including renal cell carcinoma, urothelial carcinoma, prostate cancer, penile squamous cell carcinoma, and testicular germ cell tumors. We also discuss ongoing clinical trials and candidate biomarkers to optimize patient selection and improve treatment outcomes.

AB - Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite definitive treatment, many patients with high-risk localized disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes the current evidence for neoadjuvant immunotherapy in patients with localized high-risk GU cancers including renal cell carcinoma, urothelial carcinoma, prostate cancer, penile squamous cell carcinoma, and testicular germ cell tumors. We also discuss ongoing clinical trials and candidate biomarkers to optimize patient selection and improve treatment outcomes.

KW - immune checkpoint inhibitors

KW - immunotherapy

KW - neoadjuvant

KW - penile squamous cell carcinoma

KW - prostate cancer

KW - renal cell carcinoma

KW - testicular germ cell tumors

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85213513552&partnerID=8YFLogxK

U2 - 10.3390/cancers16244127

DO - 10.3390/cancers16244127

M3 - Review article

AN - SCOPUS:85213513552

SN - 2072-6694

VL - 16

JO - Cancers

JF - Cancers

IS - 24

M1 - 4127

ER -

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies

Abstract

Keywords

Access to Document

Fingerprint

Cite this